U.S. Markets closed

Ophthotech Corporation (OPHT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.75-0.05 (-1.79%)
At close: 4:00PM EDT

2.75 0.00 (0.00%)
After hours: 4:32PM EDT

People also watch
PTLAPTCTXLRNCEMPOMED
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • W
    Wendy
    Wendy
    Fovista is over, this means that non course debt for fovista is gone. this just added tons of value to this company. And it is down? LOL
  • j
    joe
    joe
    Wendy, you were right. From now on I listen to you!
  • j
    joe
    joe
    Josh, what do you make of this news today? How important are these ongoing trials?
  • j
    joe
    joe
    Is this true >>> that this negative news today was already priced in?
  • d
    dewd
    dewd
    Should reduce the expense for this issue. Fovista off the books.
  • W
    Wendy
    Wendy
    As expected, thanks for cheap shares. Would not be surpised if this closes over 3 today
  • W
    Wendy
    Wendy
    Institutional ownership is huge here, cash with zero debt of 4.5 end of year, and zimura focus. This CO will go above cash. Watch and learn
  • W
    Wendy
    Wendy
    end of year cash is 4.50. will go over that figure by October
  • S
    Sophia
    Sophia
    Do you think this thing is done selling? Showing us a buy signal now on OPHT? the other week awe-som*sto-cks alerted this company i think. google them .
  • j
    joe
    joe
    Attorney firm(s) were investigating executive compensation as too excessive. Haven't heard any more news on this.

    With the present trials on future ones, company may have to do another capital raise as a reverse stock split is possible.

    What could happen in the next capital raise is that the board may decide to issue preferred convertible debt for promissory notes.... really worse way to raise capital.

    Perhaps selling??
  • j
    joe
    joe
    How much cash does the company now have and how long will that cash carry them for?
  • j
    joe
    joe
    Again .... but “This outcome does not affect our strategy as the Company moves forward with multiple ongoing or planned clinical programs in orphan retinal diseases coupled with multiple ongoing or planned clinical trials in back of the eye indications.”
  • j
    joe
    joe
    Never seen before -- reports failed phase 3 study and stock is up??
  • j
    joe
    joe
    Josh, please post your thoughts -- where are you?
  • j
    joe
    joe
    Judging from the very low vol of only 32,000 shares at 9:15a in premarket, this negative news may have been factored in
  • W
    Wendy
    Wendy
    2.20? crazy. now it will go up to over 4
  • D
    DMONEY
    DMONEY
    It would be years until Zimura tests are completed. Meanwhile cash continues to burn. This is worth zero.
  • M
    Metalmeister
    Metalmeister
    Do not look at executive compensation.
  • W
    Wendy
    Wendy
    It will go over 4.40 sometime before October